Medigene with strong impulseIs medigene breaking out of trendchannel or simply overbought right now. CRS and RSI strong.
Came out of a bollinger squeeze and rising.
How can you tell if its a breakout from trend? Will it continue or fall back?
−0.62CHF
−15.03 MCHF
5.61 MCHF
23.67 M
About MEDIGENE
Sector
Industry
CEO
Selwyn Ho
Website
Headquarters
Martinsried
Employees (FY)
86
Founded
1996
ISIN
DE000A1X3W00
FIGI
BBG00HPS33H5
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of MDG1 is 8.76 CHF — it has decreased by 12.97% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange MEDIGENE stocks are traded under the ticker MDG1.
MEDIGENE is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
MDG1 stock is 15.63% volatile and has beta coefficient of 0.52. Check out the list of the most volatile stocks — is MEDIGENE there?
One year price forecast for MEDIGENE has a max estimate of 2.92 CHF and a min estimate of 2.28 CHF.
MDG1 earnings for the last quarter are −0.27 CHF whereas the estimation was −0.37 CHF which accounts for 26.32% surprise. Estimated earnings for the next quarter are −0.47 CHF. See more details about MEDIGENE earnings.
MEDIGENE revenue for the last quarter amounts to 2.99 M CHF despite the estimated figure of 2.44 M CHF. In the next quarter revenue is expected to reach 2.55 M CHF.
Yes, you can track MEDIGENE financials in yearly and quarterly reports right on TradingView.
MDG1 net income for the last quarter is −8.56 M CHF, while the quarter before that showed −6.81 M CHF of net income which accounts for −25.67% change. Track more MEDIGENE financial stats to get the full picture.
Today MEDIGENE has the market capitalization of 44.09 M, it has decreased by 2.33% over the last week.
No, MDG1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MDG1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIGENE stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 86.00 employees. See our rating of the largest employees — is MEDIGENE on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIGENE technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIGENE stock shows the strong sell signal. See more of MEDIGENE technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on MEDIGENE future price: according to them, MDG1 price has a max estimate of 2.92 CHF and a min estimate of 2.29 CHF. Read a more detailed MEDIGENE forecast: see what analysts think of MEDIGENE and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDIGENE EBITDA is −13.96 M CHF, and current EBITDA margin is −249.04%. See more stats in MEDIGENE financial statements.